| Literature DB >> 17535385 |
M L Healy1, S J Dawson, R M L Murray, J Zalcberg, M Jefford.
Abstract
Insulinomas are the most common hormone-producing pancreatic neuroendocrine tumours (NETs), and patients usually present with symptoms secondary to hypoglycaemia. Octreotide has been widely used in the symptomatic treatment of patients with pancreatic NETs, including insulinomas. We describe a case of a patient with a metastatic NET, subsequently identified as a malignant insulinoma, who developed severe hypoglycaemia after treatment with long-acting octreotide.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17535385 DOI： 10.1111/j.1445-5994.2007.01371.x
Source DB: PubMed Journal: Intern Med J ISSN： 1444-0903 Impact factor: 2.048